XOMA (NASDAQ:XOMA) Now Covered by SVB Leerink

SVB Leerink started coverage on shares of XOMA (NASDAQ:XOMA) in a research note issued to investors on Monday, Marketbeat reports. The brokerage set an “outperform” rating and a $40.00 price target on the biotechnology company’s stock. SVB Leerink’s price target suggests a potential upside of 57.85% from the company’s current price.

Separately, HC Wainwright restated a “buy” rating and issued a $74.00 price target on shares of XOMA in a research report on Thursday, April 25th.

XOMA Price Performance

NASDAQ:XOMA opened at $25.34 on Monday. XOMA has a 12 month low of $13.48 and a 12 month high of $27.00. The stock has a 50 day moving average of $24.98 and a two-hundred day moving average of $20.58. The company has a current ratio of 8.68, a quick ratio of 8.68 and a debt-to-equity ratio of 1.34. The firm has a market cap of $294.96 million, a P/E ratio of -6.56 and a beta of 0.58.

XOMA (NASDAQ:XOMA) last posted its quarterly earnings data on Friday, March 8th. The biotechnology company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.13). XOMA had a negative return on equity of 25.17% and a negative net margin of 886.91%. The firm had revenue of $1.83 million for the quarter, compared to analysts’ expectations of $1.01 million. On average, analysts expect that XOMA will post -1.73 earnings per share for the current fiscal year.

Institutional Investors Weigh In On XOMA

A hedge fund recently raised its stake in XOMA stock. Stonepine Capital Management LLC increased its holdings in XOMA Co. (NASDAQ:XOMA) by 25.0% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 436,602 shares of the biotechnology company’s stock after acquiring an additional 87,203 shares during the period. XOMA makes up about 2.0% of Stonepine Capital Management LLC’s holdings, making the stock its 12th largest holding. Stonepine Capital Management LLC owned approximately 3.80% of XOMA worth $6,152,000 as of its most recent SEC filing. 95.92% of the stock is currently owned by hedge funds and other institutional investors.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.